Show simple item record

dc.contributor.authorGoyal, L
dc.contributor.authorBahleda, R
dc.contributor.authorFuruse, J
dc.contributor.authorValle, Juan W
dc.contributor.authorMoehler, MH
dc.contributor.authorOh, DY
dc.contributor.authorChang, HM
dc.contributor.authorKelley, RK
dc.contributor.authorJavle, MM
dc.contributor.authorBorad, MJ
dc.contributor.authorChen, LT
dc.contributor.authorUboha, NV
dc.contributor.authorKlumpen, HJ
dc.contributor.authorO'Dwyer, PJ
dc.contributor.authorLi, DN
dc.contributor.authorMorizane, C
dc.contributor.authorHuang, J
dc.contributor.authorBridgewater, JA
dc.date.accessioned2019-11-19T16:01:10Z
dc.date.available2019-11-19T16:01:10Z
dc.date.issued2019en
dc.identifier.citationGoyal L, Bahleda R, Furuse J, Valle JW, Moehler MH, Oh D-Y, et al. FOENIX-101: a phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. J Clin Oncol. 2019;37(4_suppl):TPS468-TPS.en
dc.identifier.doi10.1200/JCO.2019.37.4_suppl.TPS468en
dc.identifier.urihttp://hdl.handle.net/10541/622481
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.4_suppl.TPS468en
dc.titleFOENIX-101: a phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangementsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMassachusetts General Hospital, Boston, MAen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record